Advertisement

Topics

Novartis Granted Breakthrough Therapy Designation For Pediatric MS Treatment

09:30 EST 18 Dec 2017 | Pharmaceutical Processing

In a pivotal Phase III study, oral fingolimod, also known as Gilenya in the U.S. significantly reduced relapses by 82 percent in a pediatric patient population vs. interferon beta-1a intramuscular injection.
Contributed Author: 
Novartis Pharmaceuticals Corporation

Original Article: Novartis Granted Breakthrough Therapy Designation For Pediatric MS Treatment

NEXT ARTICLE

More From BioPortfolio on "Novartis Granted Breakthrough Therapy Designation For Pediatric MS Treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...